August 18, 2021
Investors in Annovis Bio Inc. have filed a proposed class action claiming the Pennsylvania biopharmaceutical company artificially inflated its stock value this spring by misrepresenting the success of its drug trials for Alzheimer's and Parkinson's diseases.